Critical Survey: Impax Laboratories (IPXL) and The Competition
Impax Laboratories (NASDAQ: IPXL) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Impax Laboratories to related companies based on the strength of its earnings, profitability, dividends, analyst recommendations, institutional ownership, risk and valuation.
This table compares Impax Laboratories and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Impax Laboratories Competitors||-3,611.88%||-55.03%||-9.16%|
This is a summary of current ratings and recommmendations for Impax Laboratories and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Impax Laboratories Competitors||944||3802||6024||164||2.49|
Impax Laboratories currently has a consensus price target of $20.07, indicating a potential downside of 12.18%. As a group, “Pharmaceuticals” companies have a potential upside of 25.05%. Given Impax Laboratories’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Impax Laboratories has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Impax Laboratories and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Impax Laboratories||$812.82 million||$144.42 million||-2.83|
|Impax Laboratories Competitors||$7.79 billion||$2.46 billion||0.99|
Impax Laboratories’ rivals have higher revenue and earnings than Impax Laboratories. Impax Laboratories is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Impax Laboratories has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Impax Laboratories’ rivals have a beta of 0.86, indicating that their average stock price is 14% less volatile than the S&P 500.
Insider and Institutional Ownership
86.3% of Impax Laboratories shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.2% of Impax Laboratories shares are held by company insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Impax Laboratories rivals beat Impax Laboratories on 7 of the 12 factors compared.
Impax Laboratories Company Profile
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Receive News & Stock Ratings for Impax Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc and related stocks with our FREE daily email newsletter.